Features of lipid metabolism in males with arterial hypertension

Objective. То determine the characteristics of lipid metabolism in practically healthy men 30—49 years old and in male patients with arterial hypertension of 1 and 2 degrees.
Materials and methods. In 207 males aged 30—49 years (67 healthy individuals and 140 patients with arterial hypertension of 1 and 2 degrees), who, depending on age and degree of arterial hypertension, were divided into 6 groups, lipid profile parameters were determined.
Results. In the age group of 30—39 years, the excess of reference values for total cholesterol in healthy men was in 51,2 % of cases, in patients with arterial hypertension of I and II degrees— 67,4 and 69,6 %, respectively; low-density lipoproteins: in healthy men in 48,8 % of cases, in patients with arterial hypertension of I and II degrees— 63,0 and 56,5 %; lipoprotein (a) content in healthy men — 10,2 [4,4; 17,7] mg/dl, in patients with arterial hypertension of I and II degrees — 10,3 [4,9; 24,5]mg/dl and 14,3 [6,3; 20,5]mg/dl; apoB content in healthymen — 0,88 [0,72; 1,20]g/l, in patients with arterial hypertension of I and II degrees— 0,92 [0,69; 1,04] g/l and 0,89 [0,79; 1,44] g/l. In the age group of 40—49 years, the excess of reference values for total cholesterol in healthy men was in 79,2 % of cases, in patients with arterial hypertension of I and II degrees — 82,0 and 84,4 %, respectively; low-density lipoproteins: in healthy men in 75,0 % of cases, in patients with arterial hypertension of I and II degrees— 64,1 and 75,0 %; lipoprotein (a) content in healthy men— 8,7 [5,3; 13,2] mg/dl, in patients with arterial hypertension of I and II degrees— 13,0 [5,5; 24,1] mg/dl and 11,5 [6,5; 21,2] mg/dl; apoB content in healthy men — 0,94 [0,78; 1,25] g/l, in patients with arterial hypertension of I and II degrees — 0,93 [0,84; 1,20] g/l and 1,01 [0,83; 1,24] g/l.
Conclusion. A high incidence of dyslipidemia was revealed in all study groups.

1. Jagannathan R., Patel S. A., АН M. K., Narayan К. M. V. Global Updates on Cardiovascular Disease Mortality Trends and Attribution of Traditional Risk Factors. Curr. Diab. Rep. 2019;19 (7): 44.

2. Dattani S., Samborska V., Ritchie H., Roser M. CardiovascularDiseases. OurWorld In Data. 2023. Available at: https://ourworldindata.org/cardiovascular-diseases?insight=cardiovascular-diseases-are-the-most-common-cause-of-death-worldwide#key-insights (аccessed 12 February, 2024).

3. STEPS: Prevalence of risk factors for noncommunicable diseases in the Republic of Belarus, 2020. Available at: https://cdn.who.int/media/docs/default-source/ ncds/ncd-surveillance/data-reporting/belarus/belarus_steps_report_2020_ru.pdf?sfvrsn=d89690ac_1&download=true (аccessed 12 February, 2024). [(in Russian)]

4. Prevalence of risk factors for non-communicable diseases in the Republic of Belarus STEPS 2016. 2017 г. Available at: https://cdn.who.int/media/docs/default-source/ ncds/ncd-surveillance/data-reporting/belarus/belarus_2016_steps_r3port_ru.pdf?sf/rsn=ba77bf51_1&download=true (аccessed 12 February, 2024). [(in Russian)]

5. Kamyshnikov V. S., Alekhnovich L. I., Kuz’menko A. T Laboratory diagnosis of coronary heart disease. Tutorial. Minsk: Obrazovanie i vospitanie; 2015:360. [(in Russian)]

6. Visseren F. L. J., Mach F, Smulders Y. M. et al. ESC Scientific Document Group, 2021. ESC Guidelines on cardiovascular disease prevention in clinical practice: European Heart Journal. 2021; 42: 3227—37.

7. Zueva I. B., Baratashvili G. G., Krivonosov D. S. i dr. Modern ideas about the role of lipoprotein (a) in the development of cardiovascular events. Therapy options. Arterial’naya gipertenziya. 2016; 22(3): 232—43. [(in Russian)]

8. Macha F, Baigentb C., CatapanoA. L. etal. 2019 ESC/ EAS guidelines for the management of dyslipidaemias: Lipid modification to reduce cardiovascular risk. Atherosclerosis. 2019; 290: 140—205.

9. Rallidis L. S., Pavlakis G., Foscolou A. et al. High levels of lipoprotein (a) and premature acute coronary syndrome. Atherosclerosis. 2018; 269: 29—34.

10. Chyu K. Y., Shah P K. HDL/ApoA-1 infusion andApoA-1 gene therapy in atherosclerosis. Front. Pharmacol. 2015; 6: 187.

11. Zamanian-Daryoush M., DiDonato J. A. Apolipoprotein A-I and Cancer. Front. Pharmacol. 2015; 6: 265.

12. Tebloev K. I., Arabidze G. G., Polyakova O. V. i dr. The role of lipoprotein(a) and apolipoprotein B-100 in the development of coronary heart disease. Rossijskij kardiologicheskij zhurnal. 2005; 5(55): 20—3. [(in Russian)]

13. 2021 ESC recommendations for the prevention of cardiovascular disease in clinical practice. Rossijskij kardiologicheskij zhurnal. 2022;27(7):5155. Available at: https://doi.org/10.15829/1560-4071-2022-5155 (аccessed 12 February, 2024). [(in Russian)]

14. Yaseen R. I., El-Leboudy M. H., El-Deeb Yaseen H. M. The relation between ApoB/ApoA-1 ratio and the severity of coronary artery disease in patients with acute coronary syndromeю The Egyptian Heart Journal. 2021; 73: 24.

15. Kutyrina I. M. Obesity-associated glomerulopathy: mechanisms of development, clinical course. Terapevticheskij arhiv. 2017; 89(6): 97—101. [(in Russian)]

16. Nathir I., Abd Aziz F, Hashim R. Association Between Apolipoprotein B and Coronary Artery Disease Among Hypertensive Patients: A Systematic Review of the Prospective and Retrospective Studies. Cureus. 2023; 15(12): e49854.

17. Plehova N. G., Nevzorova V. A., Rodionova L. V. i dr. Indicators of lipoprotein metabolism in young patients with arterial hypertension. Vestnik sovremennoj klinicheskoj mediciny. 2019; 12(4): 44—50. [(in Russian)]

18. Erqou S., Kaptoge S., Perry P. L. et al. Lipoprotein (a) concentration and the risk of coronary heart disease, stroke, and nonvascular mortality JAMA. 2009; 302(4): 412—23.

19. Emel’janchik V. S., Marilovceva O. V., Homchenkov R. V. i dr. Lipoprotein (a) in the diagnosis of cardiovascular risk. values of lipoprotein (a) and apolipoprotein in the adult population of Krasnoyarsk. Rossijskij kardiologicheskij zhurnal. 2023; 28(7): 65—70. [(in Russian)]